PET Scan
The prognostic value of F18 Fluorothymidine positron emission tomography for assessing the response of malignant pleural mesothelioma to chemotherapy – A prospective cohort study
Journal of Medical Imaging and Radiation Oncology 2023 October 29 [Link] Isaac J May, Anna K Nowak, Roslyn J Francis, Martin A Ebert, Satvinder S Dhaliwal Abstract Introduction: Malignant pleural mesothelioma is difficult to prognosticate. F18-Fluorodeoxyglucose positron emission tomography (FDG PET) shows promise for response assessment but is confounded by talc pleurodesis. F18-Fluorothymidine (FLT) PET…
Read MorePrognosis prediction of patients with malignant pleural mesothelioma using conditional variational autoencoder on 3D PET images and clinical data
Medical Physics 2023 August 31 [Link] Hidetoshi Matsuo, Kazuhiro Kitajima, Atsushi K Kono, Kozo Kuribayashi, Takashi Kijima, Masaki Hashimoto, Seiki Hasegawa, Koichiro Yamakado, Takamichi Murakami Abstract Background: Deep learning (DL) has been widely used for diagnosis and prognosis prediction of numerous frequently occurring diseases. Generally, DL models require large datasets to perform accurate and reliable…
Read MoreA rare presentation of malignant mesothelioma of the tunica vaginalis managed with immunotherapy and review of the literature
Clinical Case Reports 2023 June 22 [Link] Kritika Mishra, Shihab Siddiquee, Anna Rachelle Mislang Abstract Key clinical message: We describe the first case in literature of malignant mesothelioma of the tunica vaginalis that has shown partial response to systemic immunotherapy (ipilimumab-nivolumab) post orchiectomy, warranting further investigation in a trial setting. Abstract: We present a case…
Read MoreComparison of the role of 18 F-fluorodeoxyglucose PET/computed tomography and 68 Ga-labeled FAP inhibitor-04 PET/CT in patients with malignant mesothelioma
Nuclear Medicine Communications 2023 April 28 [Link] Yunus Güzel, Halil Kömek, Canan Can, İhsan Kaplan, Ferat Kepenek, Senar Ebinç, Mehmet Perver Büyükdeniz, Cihan Gündoğan, Zeynep Oruç Abstract Objective: In this study, we aimed to compare the role of 68 Ga-labeled FAP inhibitor ( 68 Ga-FAPI)-04 PET/computed tomography (CT) and 18 F-fluorodeoxyglucose ( 18 F-FDG) PET/CT…
Read MoreOne Third of Malignant Pleural Mesothelioma Shows High Immunohistochemical Expression of MSLN or CXCR4 Which Indicates Potent Candidates for Endo-Radiotherapy
International Journal of Molecular Sciences 2023 March 28 [Link] Thomas Hager, Sabrina Borchert, Michael Wessolly, Alexander Mathilakathu, Elena Mairinger, Jens Kollmeier, Thomas Mairinger, Balazs Hegedus, Kristina Greimelmaier, Jeremias Wohlschlaeger, Ken Herrmann, Fabian Dominik Mairinger Abstract Malignant pleural mesothelioma (MPM) is a mainly asbestos-related tumour associated with a very poor prognosis. Therapeutic approaches include multimodal therapy…
Read MoreMalignant Peritoneal Mesothelioma Features Shown by FDG-PET/CT
Cancer Diagnosis & Prognosis 2022 November 3 [Link] Kozo Kuribayashi, Kazuhiro Kitajima, Toshiyuki Minami, Masataka Ikeda, Koichiro Yamakado, Takashi Kijima Abstract Background/aim: Malignant peritoneal meso-thelioma (MPeM) has no specific imaging findings that can distinguish it from other peritoneal tumors and the accuracy of peritoneal cytology is low, therefore definitive diagnosis is usually performed by histology.…
Read MoreFactors affecting the life expectancy in malignant pleural mesothelioma: Our 10 years of studies and experience
Medicine 2022 September 30 [Link] Filiz Cimen, Yetkin Agackiran, Sevim Düzgün, Melike Aloglu, Aysegül Senturk, Sükran Atikcan Abstract Malignant pleural mesothelioma (MPM) is an aggressive tumor with a poor prognosis. In our study, we aimed to investigate the specific clinical, laboratory, and radiological features of the tumor and the prognostic effect of SUVmax (maximum standardized…
Read MoreFDG PET/CT for Staging and Restaging Malignant Mesothelioma
Seminars in Nuclear Medicine 2022 August 11 [Link] Egesta Lopci, Angelo Castello, Luigi Mansi Abstract Malignant mesothelioma is an aggressive tumor originating from the mesothelial cells and presenting in general with a very poor prognosis. The pleural localization represents the prevailing disease site, while peritoneal involvement is commonly rare. The WHO classifies mesotheliomas into epithelioid,…
Read MoreThrombocytopenia as an Immune-Related Adverse Event in Malignant Pleural Mesothelioma: A Case Report
JTO Clinical and Research Reports 2022 June 9 [Link] Takaaki Tanaka, Shoji Asakura, Kazuya Hisamatsu, Nobukazu Fujimoto Abstract A 69-year-old man presented with a pulmonary opacity at a regular medical check-up. He had been exposed to asbestos in a chemical fiber manufacturing setting. Result of positron emission tomography with computed tomography (CT) revealed fluorodeoxyglucose accumulations…
Read MorePrimary malignant pericardial mesothelioma with a survival of 2.5 years: a case report
Translational Cancer Research 2022 May [Link] Yan Yan, Wenli Lv, Yinghao Luo, Jianlin Hu, Jie Yang Abstract Background: Primary malignant pericardial mesothelioma (PMPM) is a highly malignant tumor originating in the pericardium serosum with clinical manifestations presenting as constrictive pericarditis, with pericardial tamponade and heart failure. Malignant pericardial mesothelioma is rare and has a poor…
Read More